Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
$16.91 +0.91 (5.69%)
As of 03/05/2021 15:59:58 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.